首页> 美国卫生研究院文献>other >Clear Cell Papillary Renal Cell Carcinoma and RenalAngiomyoadenomatous Tumor – Two Variants of a MorphologicImmunohistochemical and Genetic Distinct Entity of Renal CellCarcinoma
【2h】

Clear Cell Papillary Renal Cell Carcinoma and RenalAngiomyoadenomatous Tumor – Two Variants of a MorphologicImmunohistochemical and Genetic Distinct Entity of Renal CellCarcinoma

机译:透明细胞乳头状肾细胞癌和肾血管肌腺瘤性肿瘤–形态学的两个变体肾细胞的免疫组织化学和遗传不同实体癌

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Clear cell papillary renal cell carcinoma (ccpRCC) and renal angiomyoadenomatous tumor (RAT) share morphologic similarities with clear cell (ccRCC) and papillary renal cell carcinoma (pRCC). It is a matter of controversy whether their morphologic, immunophenotypic and molecular features allow the definition of a separate renal carcinoma entity. The aim of our project was to investigate specific renal immunohistochemical biomarkers involved in the hypoxia-inducible factor pathway and mutations in the VHL gene to clarify the relationship between ccpRCC and RAT. We investigated 28 ccpRCC and 9 RAT samples by immunohistochemistry using 25 markers. VHL gene mutations and allele losses were investigated by Sanger sequencing and fluorescence in situ hybridization (FISH). Clinical follow-up data were obtained for a subset of the patients. No tumor recurrence or tumor-related death was observed in any of the patients. Immunohistochemistry and molecular analyses led to the reclassification of three tumors as ccRCC and TFE3 translocation carcinomas. The immunohistochemical profile of ccpRCC and RAT samples was very similar but not identical, differing from both ccRCC and pRCC. Especially, the parafibromin and hKIM-1 expression exhibited differences in ccpRCC/RAT comparedwith ccRCC and pRCC. Genetic analysis revealed VHL mutations in 2/27(7%) and 1/7 (14%) ccpRCC and RAT samples, respectively. FISHanalysis disclosed a 3p loss in 2/20 (10 %) ccpRCC samples. ccpRCC andRAT have a specific morphologic and immunohistochemical profile but they sharesimilarities with the more aggressive renal tumors. Based on our results, weregard ccpRCC/RAT as a distinct entity of renal cell carcinomas.
机译:透明细胞乳头状肾细胞癌(ccpRCC)和肾血管平滑肌腺瘤瘤(RAT)与透明细胞(ccRCC)和乳头状肾细胞癌(pRCC)具有相似的形态。它们的形态,免疫表型和分子特征是否允许定义一个单独的肾癌实体,这是一个有争议的问题。我们项目的目的是研究参与缺氧诱导因子途径的特定肾脏免疫组织化学生物标记物和VHL基因突变,以阐明ccpRCC与RAT之间的关系。我们使用25种标记物通过免疫组织化学研究了28个ccpRCC和9个RAT样品。通过Sanger测序和荧光原位杂交(FISH)研究了VHL基因突变和等位基因缺失。获得了部分患者的临床随访数据。在任何患者中均未观察到肿瘤复发或与肿瘤相关的死亡。免疫组织化学和分子分析导致三种肿瘤被重新分类为ccRCC和TFE3易位癌。 ccpRCC和RAT样品的免疫组织化学特征与ccRCC和pRCC非常相似但不完全相同。尤其是,与之相比,副纤蛋白和hKIM-1表达在ccpRCC / RAT中表现出差异ccRCC和pRCC。遗传分析显示VHL突变在2/27(7%)和1/7(14%)的ccpRCC和RAT样本。鱼分析揭示了2/20(10%)ccpRCC样品的3p损失。 ccpRCC和RAT具有特定的形态学和免疫组化谱,但它们共享与更具侵略性的肾肿瘤相似。根据我们的结果,我们将ccpRCC / RAT视为肾细胞癌的独特实体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号